Lawmakers eye lame duck for unfinished business on insulin
WASHINGTON — A bipartisan Senate duo is still working to pass a bill to overhaul insulin prices, but the outlook is complicated by the messy drug pricing system, politics and a busy congressional calendar.
Tribune News Service ·